Perspectives

Targeted Oncology

, Volume 5, Issue 3, pp 217-227

First online:

Immune therapeutic targeting of glioma cancer stem cells

  • Mustafa Aziz HatibogluAffiliated withDepartment of Neurosurgery, The University of Texas M. D. Anderson Cancer Center
  • , Jun WeiAffiliated withDepartment of Neurosurgery, The University of Texas M. D. Anderson Cancer Center
  • , Adam Sauh Gee WuAffiliated withDepartment of Neurosurgery, The University of Texas M. D. Anderson Cancer Center
  • , Amy B. HeimbergerAffiliated withDepartment of Neurosurgery, The University of Texas M. D. Anderson Cancer Center Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential of immune targeting of the gCSC and propose several novel solutions.

Keywords

Glioma cancer stem cells STAT3 Glioblastoma multiforme Immunotherapy